Longeveron Announces Pricing of $5.25 Million Public Offering

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as

Related Keywords

Delaware ,United States ,New York ,Miami ,Florida ,Derek Cole ,Company Class ,Exchange Commission ,Hc Wainwright Co ,Exchange Commission On ,Investor Relations Advisory Solutions ,Nasdaq ,Longeveron Or Company ,Longeveron Inc ,Aging Related Frailty ,Looking Statements ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Annual Report ,Quarterly Reports ,Current Reports ,Relations Advisory ,